Protamine Sulfate

Summary

Protamine Sulfate (CHEMBL1201651) is an approved unknown (ATC V03AB14).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: V03AB14
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201651
Name	Protamine Sulfate
Type	Unknown
Max phase	4
ATC	V03AB14

Also known as: Novo protamine sulfate, Prosulf, Protamine, Protamine sulfate, Protamine sulphate, Protamines, Protamini sulfas, Sulfate de protamine, Sulfato de protamina, PROTAMINE SULFATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
Not specified	4
PHASE4	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02974660	PHASE4	COMPLETED	Protamine Sulfate During Transcatheter Aortic Valve Implantation
NCT03140631	PHASE4	COMPLETED	Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation
NCT05774691	PHASE4	COMPLETED	Routine Versus Selective Protamine Administration to Reduce Bleeding Complications After Transcatheter Aortic Valve Implantation (POPular ACE TAVI)
NCT00073593	PHASE3	COMPLETED	Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB
NCT07477977	Not specified	RECRUITING	Dose for Reversal of Heparin After Cardiopulmonary Bypass
NCT00684450	Not specified	COMPLETED	Cardiac Surgery: In Vivo Titration of Protamine
NCT02644785	Not specified	COMPLETED	Serum Tryptase Levels During Cardiac Surgery, Diagnosis and Treatment Decisions for Allergic Reactions
NCT03787641	Not specified	UNKNOWN	Systematic Evaluation of Protamine Doze in Cardiac Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).